EU Approves SARCLISA® (isatuximab-irfc) for the Treatment of Transplant-Eligible Newly Diagnosed Multiple Myeloma  (https://www.myeloma.org/news-events/multiple-myeloma-news/eu-approves-sarclisar-isatuximab-irfc-treatment-transplant-eligible-newly-diagnosed-multiple)